Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

uch patients are characterized by presence of chromosomal abnormalities (i.e., deletions of chromosome 17p or 11q) or short remissions (less than 3 years) after standard chemo-immunotherapy. To develop an alternative therapy regimen for this patient population, researchers explored the combination of ibrutinib and the anti-CD20 antibody rituximab in high-risk CLL.

In this Phase II study conducted at The University of Texas MD Anderson Cancer Center in Houston, ibrutinib was given in combination with rituximab to evaluate its potential to accelerate and improve CLL patient responses. Forty patients were treated with 420 mg of ibrutinib daily in combination with weekly rituximab for four weeks, followed by ibrutinib daily plus monthly rituximab until month six, followed by single-agent ibrutinib.

Positive responses to therapy were shown among the vast majority of treated patients. At four months of follow-up, the overall response rate was 85 percent and almost all (38 of 40) patients continued on therapy without disease progression. Of the 20 patients evaluable for early response, 17 achieved a partial remission. Patient health questionnaires also noted improvements in health and the quality of life of all treated patients.

Overall, the regimen was well-tolerated among participants, with little severe toxicity that was largely unrelated and short in duration. After treatment with ibrutinib-rituximab (iR) combination therapy, most cases of early lymphocytosis (increase in white blood cells that is a sign of infection), due to the ibrutinib-induced shift of CLL cells from lymph node tissues into the blood, peaked early and resolved; at four months of follow-up, only three treated patients had lymphocytosis that had not yet resolved. This shorter lymphocytosis duration, when compared to single-agent use of ibrutinib, is presumably related to the addition of rituximab.

"We know that high-risk CLL patients struggle with the effects of
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 ... of the HIMSS EMR Adoption Model, the hospital ... improve patient engagement and automate processes. The leadership ... from paper-driven to electronic workflows, patient registration still ... copies of consents. With HIMSS Stage 7 attestation ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Corporate ... behalf of MEBC, an Alliance Award for excellence ... during FOCUS 2015, JDA’s annual user conference which ... retail and wholesale distribution sectors. This award recognizes ... are receiving services that advance their supply chain ...
(Date:5/6/2015)... 06, 2015 The Beryl Institute announces ... of Patient Experience Journal (PXJ), an international, open access, ... understanding and improving patient experience. The second volume of ... conversation globally, helps align the voices engaged and provides ... Published in association with The Beryl Institute, Volume 2, ...
(Date:5/6/2015)... Marketing Maven announces a ... sanitation and hygiene nonprofit by GuideStar’s Philanthropedia. , “WaterAid ... and it brings our agency great joy to work ... “The ongoing relationship between WaterAid and Marketing ... learn about and support the nonprofit as they aim ...
(Date:5/6/2015)... 06, 2015 Wolters Kluwer , ... and students, announced today that in a survey of ... use of the clinical decision support resource improves the ... of 2014, UpToDate users in more than 170 countries ... month, on average. In Germany alone, 95% of all ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... Diseases than Ever ... ... childhood influenza and adolescent meningococcal,vaccinations are included in the 2008 Childhood ... Control and,Prevention (CDC), the American Academy of Pediatrics (AAP), and the,American ...
... NEW YORK, Jan. 11 The Substance Abuse ... from the National Survey on Drug Use and ... S. aged 12 to 25 have abused non-prescription,over-the- ... high at least once,in their lifetime. This announcement ...
... health care reform is too important, the stakes for, Californians ... ... changes., SACRAMENTO, Calif., Jan. 11 As the ... hammered out by Governor Arnold Schwarzenegger and Assembly,Speaker Fabian Nunez, the state,s ...
... genetic, biological causes could lead more to feel comfortable ... When people understand the genetics and biology of anorexia ... the eating disorder for their illness, says a University ... , "This is a potentially important finding because it ...
... diet and lifestyle are at root of reduced risk, , , FRIDAY, ... in your blood may reduce your risk of stroke, new research ... C in their blood had a 42 percent lower risk of ... which is in the January issue of The ...
Cached Medicine News:Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:Health Groups Release 2008 Immunization Schedules 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse 4Health News:Insurance Agents Call for State Senate to Improve California's Health Care Reform Compromise 2Health News:Science Could Erase Stigma of Anorexia 2Health News:Vitamin C May Play Role in Stroke Prevention 2Health News:Vitamin C May Play Role in Stroke Prevention 3
(Date:5/6/2015)... 2015  CTI BioPharma Corp. (NASDAQ and MTA: CTIC) ... March 31, 2015. "After reporting ... trial of pacritinib during the quarter, we have subsequently ... who are excited by the potential opportunity for pacritinib ... treatment of patients with myelofibrosis, specifically in the portion ...
(Date:5/6/2015)... May 6, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... first quarter ended March 31, 2015 and provided an ... "We continue to make progress across our targeted oncology ... Ph.D., president and CEO, Mirati. "We look forward to ... Society of Clinical Oncology meeting at the end of ...
(Date:5/6/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... with an emphasis on the treatment of primary and ... months ended March 31, 2015.  Highlights ... , Achieved quarterly product revenue of $0.44 million, an ... quarter of 2014; , Activated a prospective patient ...
Breaking Medicine Technology:CTI BioPharma Reports First Quarter 2015 Financial Results 2CTI BioPharma Reports First Quarter 2015 Financial Results 3CTI BioPharma Reports First Quarter 2015 Financial Results 4CTI BioPharma Reports First Quarter 2015 Financial Results 5CTI BioPharma Reports First Quarter 2015 Financial Results 6CTI BioPharma Reports First Quarter 2015 Financial Results 7CTI BioPharma Reports First Quarter 2015 Financial Results 8CTI BioPharma Reports First Quarter 2015 Financial Results 9Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 2Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 3Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 4Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 5Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... Cardica, Inc. (Nasdaq: CRDC ) today ... marketing. In this role, Mr. Littel will be responsible ... Cardica,s existing cardiac surgery devices and its planned MicroCutter™ ... surgery. "Chris brings experience as a successful ...
... -- ShangPharma Corporation (NYSE: SHP ) ... and biotechnology research and development outsourcing company, today ... subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired the ... River") Shanghai research facility. As ...
Cached Medicine Technology:Cardica Appoints Christopher Littel VP, Sales and Marketing 2Cardica Appoints Christopher Littel VP, Sales and Marketing 3ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River 2
... rod, and screw system designed to treat various ... utilizes a low profile design that incorporates anatomic ... The load sharing design of the 5.5 Titanium ... be applied when used with proper anterior column ...
BLF21A Alarm Model measures microcirculation in 1 cubic mm of tissue for real-time assessment of perfusion....
A portable, easy to use, dual-channel laser-Doppler tissue perfusion and temperature monitoring system, at a remarkably affordable price....
... featured laser doppler system for continuous ... multiple tissue sites. This latest generation ... Processing (DSP) and laser Doppler flowmetry ... to use, multi-channel monitor, setting new ...
Medicine Products: